Preview

Meditsinskiy sovet = Medical Council

Advanced search

Possible benefits of evaluation the coefficient of variation of active substance of a drug from different manufactures based on benzydamine hydrochloride example

https://doi.org/10.21518/2079-701X-2019-8-102-104

Abstract

Acute respiratory viral infection (ARVI) is one of the most common causes of morbidity in Russia. The incidence rate is high regardless of age or social group [1]. Sore throat is the most common symptom during ARVI, prevalence rate is 95%[2]. Symptomatic treatment of ARVI requires the use of various drugs, including drugs for pain in the throat. Such preparations are widely represented on the market, while they have a different form and different composition. One of the most popular are sprays containing benzydamine hydrochloride. Professional associations recommend using Benzydamine hydrochloridewhile sore throat, also in paediatric practice [3].In connection with a large number of generics, the issue of standardization of such sprays is topical. To compare the range of the actual concentration of the active substance in interchangeable preparations with different trade names, a comparative determination of the concentrations of benzydamine hydrochloride in sprays of 4 trade names was carried out in 6 different series in each. The quantitative determination was carried out by HPLC with a UV detector. As a result, the active substance concentration ranges were determined in 6 batches of the preparation of each trade name, and the coefficient of variation of concentrations was calculated and conclusions were made on the difference in the indicated indices among preparations of various manufacturers.

About the Authors

V. V. Smirnov
Federal State Budgetary Institution «State Scientific Center «Institute of Immunology» of the Federal Medical-Biological Agency
Russian Federation

Cand. of Sci. (Pharm.), Associate Professor, Head of the Clinical Pharmacology Laboratory, the Federal State Budgetary Institution «State Research Center «Institute of Immunology» of the Federal Medical-Biological Agency

SPIN-code: 4171-3871



E. A. Egorenkov
Federal State Budgetary Institution «State Scientific Center «Institute of Immunology» of the Federal Medical-Biological Agency
Russian Federation

Cand. of Sci. (Pharm.), Junior Researcher of the Clinical Pharmacology Laboratory, the Federal State Budgetary Institution «State Research Center «Institute of Immunology» of the Federal MedicalBiological Agency

SPINcode: 5936-4008



References

1. On the State of Sanitary and Epidemiological Welfare of the Population in the Russian Federation in 2015: State Report. M.: Federal Service for Supervision of Consumer Rights Protection and Human Welfare.] (In Russ).

2. Dvoretsky L.I., Yakovlev S.V. Errors in the antibacterial treatment of respiratory tract infections in outpatient practice. Lechaschy Vrach. 2003;8.] (In Russ).

3. Acute tonsillitis in children. Clinical guidelines. Union of Pediatricians of Russia, 2016.] (In Russ).

4. Malyarenko E.V. Experts called the most sold drug in 2017. 2017. Available from: https://www.rbc.ru/business/24/04/2018/5adebe5e9a7 947ab8d8c9e27.] (In Russ.)

5. Jiang W., Makhlouf F., Schuirmann D.J. et al. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion. AAPS J. 2015 Jul;17(4):891–901.


Review

For citations:


Smirnov VV, Egorenkov EA. Possible benefits of evaluation the coefficient of variation of active substance of a drug from different manufactures based on benzydamine hydrochloride example. Meditsinskiy sovet = Medical Council. 2019;(8):102-104. (In Russ.) https://doi.org/10.21518/2079-701X-2019-8-102-104

Views: 851


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)